Given the eyebrow-raising cash component in Celgene's new deal with Nogra, we thought it would be fun to list the top 10 upfronts paid for experimental drugs, ranked simply according to the cash included in the upfront--no surer sign of what a company really thinks about the potential of an experimental therapy or portfolio.
Close to a year after Forma Therapeutics' executive team hammered out a partnership with Celgene packed with $200 million in early-stage payouts, the big biotech outfit has come back with a $600 million discovery deal that might eventually lead the pair to the M&A altar.
Looking over the 416 licensing deals EvaluatePharma tracked for the first six months of the year, total upfronts and deal values for Phase II programs were well ahead of Phase III--as well as the pace set for mid-stage pacts in the first half of 2012.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email |...
Forma Therapeutics has enlisted some expert assistance through Cancer Research UK's extensive scientific network to drum up a slate of new cancer drug programs in the field of protein homeostasis, with plans to populate a portfolio of virtual companies that can be partnered or sold to its biopharma clientele.
Celgene and Forma have agreed to a broad collaboration in the field of protein homeostasis, which involves quality-control pathways in cells that play roles in cancer, neurodegenerative disorders and other diseases.
As biotechs face monumental funding challenges and a stingy IPO market, young companies are investing in business models that have the potential to maximize the value of their drug candidates.
Just days after inking an $815 million cancer drug discovery pact with Boehringer Ingelheim, Forma Therapeutics agreed to put its fast-growing small molecule ops to work for J&J's Janssen in a
Forma Therapeutics has nabbed an $815 million deal--$65 million of that in an upfront payment and the rest in pre-commercial milestones--to direct its growing drug discovery engine to new small
Genentech says that it's lined up the worldwide rights to a preclinical cancer program held by Forma Therapeutics in an "innovative" pact, but it's leaving all the numbers blank in its release.